Send Orders for Reprints to [email protected] 38
The Open AIDS Journal, 2015, 9, 38-44
Open Access
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens Lisa L. Ross*,1, Mark F. Cotton2, Haseena Cassim3, Eugeny Voronin4, Naomi Givens5, Jorg Sievers5, and Katharine Y. Cheng5 For the APV29005 & APV20002 Pediatric Study Groups 1
ViiV Healthcare, Research Triangle Park, NC, USA
2
Department of Pediatrics and Child Health, Children’s Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg, South Africa 3
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
4
Republic Hospital of Infectious Disease, St. Petersburg, Russian Federation
5
GlaxoSmithKline, Stockley Park, UK Abstract: Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretroviral therapy (ART)naïve and ART-experienced patients were enrolled. Patients met VF criteria by either failing to suppress HIV-RNA to
The Open AIDS Journal, 2015, 9, 38-44
Open Access
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens Lisa L. Ross*,1, Mark F. Cotton2, Haseena Cassim3, Eugeny Voronin4, Naomi Givens5, Jorg Sievers5, and Katharine Y. Cheng5 For the APV29005 & APV20002 Pediatric Study Groups 1
ViiV Healthcare, Research Triangle Park, NC, USA
2
Department of Pediatrics and Child Health, Children’s Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg, South Africa 3
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
4
Republic Hospital of Infectious Disease, St. Petersburg, Russian Federation
5
GlaxoSmithKline, Stockley Park, UK Abstract: Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretroviral therapy (ART)naïve and ART-experienced patients were enrolled. Patients met VF criteria by either failing to suppress HIV-RNA to
